Merck Drug for Rare Form of High Blood Pressure Gets US Nod (4)

Merck & Co. won US approval for a new treatment for a rare, dangerous form of high blood pressure that’s expected to be among the company’s hits as sales from successful older drugs begin fading later this decade.

The drug, known as sotatercept, will be sold as Winrevair in the US, according to information posted on the Food and Drug Administration website. It will cost $14,000 per vial and will be taken every three weeks, according to Merck. At that rate, the drug would cost about $242,000 a year, although some patients will require more.

WATCH: Merck CEO Robert M. Davis discusses the US approval of Winrevair, a new treatment for a rare, dangerous form of high blood pressure.

Source: Bloomberg

The clearance is crucial ...